AGP
PSTX

Artia Global Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Artia Global Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-86,002
Closed -$274K – 56
2024
Q1 		$274K Buy
+86,002
New +$287K 0.06% 48

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Artia Global Partners's PSTX Position: Q2 2024 in Review

Artia Global Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2024, closing a stake of 86,002 shares — an estimated $274K sold.

Artia Global Partners first reported a position in PSTX in Q1 2024 and held it in 1 quarter. The position peaked at $274K in Q1 2024. 93 funds tracked by Wall St. Rank hold PSTX as of Q2 2024.

  • Artia Global Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Artia Global Partners sold 86,002 Poseida Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $274K.
  • Artia Global Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Artia Global Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $274K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.